DEBIOPHARM COLLABORATES WITH INNOCENTIVE FOR THE LAUNCH OF A GLOBAL CHALLENGE TO DEVELOP A SINGLE-DOSE mRNA COVID-19 VACCINE
Lausanne, Switzerland (ots) - - Currently approved COVID-19 vaccines based on messenger RNA (mRNA) technology require two injections, given several weeks apart, for optimal protection against the virus - Debiopharm has launched a vaccine innovation challenge to a pool of international “problem Solvers” within ...